What do systematic reviews say?

Short‐acting insulin analogues vs regular human insulin

• Short‐acting insulin analogues versus regular human insulin for adult, non‐pregnant persons with type 2 diabetes… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 2 participants
  Very low
• Short‐acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Insulin analogues vs biphasic insulin

The review found no eligible studies for this question.

• Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: insulin detemir vs NPH insulin

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 870 participants
  Low
• (Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 873 participants
  Very low

Summary of findings: insulin detemir vs insulin glargine

The review found no eligible studies for this question.

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: insulin degludec vs insulin detemir

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 454 participants
  Low

Summary of findings: insulin degludec vs insulin glargine

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1042 participants
  Very low

Insulin glargine vs NPH insulin

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1013 participants
  Low